Search bioRxiv⌕ Search

Biology subjects

Friedman, P.

Publications and source records attributed to Friedman, P..

2 recordsLinked to original sources

Structural factors of RGS14 regulating hormone-dependent phosphate transport mediated by NPT2A

The NPT2A sodium phosphate cotransporter-2a mediates basal and parathyroid hormone (PTH)- and fibroblast growth factor-23 (FGF23)-regulated phosphate transport in kidney proximal tubule cells. Both basal and hormone-sensitive transport require sodium hydrogen exchanger regulatory factor-1 (NHERF1), a scaffold protein with 2 PDZ domains. NPT2A binds to PDZ1. RGS14 persistently represses hormone action by binding to PDZ2. RGS14 contains an RGS domain, two Ras/Rap-binding domains (RBD1, RBD2), a G protein regulatory (GPR) motif, and a carboxy-terminal PDZ ligand. The intrinsic RGS14 domains cannot explain its regulatory effects on hormone-sensitive phosphate transport because these actions are mediated not only by the PTH receptor, a G protein-coupled receptor (GPCR) but also by fibroblast growth factor receptor-1 (FGFR1), a receptor tyrosine kinase that is not governed by G protein activity. Here, we sought to identify the RGS14 structural elements mutually controlling PTH and FGF23 action. RGS14 truncation constructs lacking upstream sequence and the RGS domain were fully functional. Removing the linker sequence between RGS and RBD1 domains was sufficient to abrogate RGS14 action. Examination of the alpha-helical linker region suggested candidate serine residues that might facilitate regulatory activities. Ser266 and Ser269 replacement by Ala abolished RGS14 regulatory actions on hormone-sensitive phosphate transport and binding to NHERF1. The results establish that RGS14 actions require targeted phosphorylation within the linker and an intact PDZ ligand.

cell biology↗

The Safety of a Therapeutic Product Composed of a Combination of Stem Cell Released Molecules from Adipose Mesenchymal Stem Cells and Fibroblasts

Stem cell transplants have demonstrated life-saving capabilities for some blood diseases, and the molecules and exosomes released from stem cells are currently in therapeutic development for a number of diseases and conditions, including neurodegenerative diseases, heart conditions, glaucoma, hearing loss, and skin diseases. Stem cell science is a relatively new science, and therapeutic development using stem cells, even approved stem cell therapies for blood diseases, is in need of a better understanding of mechanisms of action and acute and long-term safety profiles. Here we performed a number of safety tests for a stem cell-based therapeutic comprised of the stem cell released molecules from a combination of adipose derived mesenchymal stem cells and fibroblasts that have demonstrated efficacy in a number of conditions. Using in vitro, in vivo, and skin sensitivity studies in humans, the stem cell therapeutic comprised of stem cell released molecules was shown to have an excellent safety profile when tested for toxicity, mutagenicity, tumorigenesis, ocular toxicity, inflammation, and irritation.

bioengineering↗